These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8672306)

  • 1. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1996 May; 48(5):467-72. PubMed ID: 8672306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A long-term clinical effect of selegiline hydrochloride on Parkinson's disease].
    Mizuno Y; Kondo T; Takubo H; Yokochi F
    No To Shinkei; 1994 May; 46(5):465-71. PubMed ID: 8060685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
    Kondo T; Takubo H; Yokochi F; Okuma Y; Mizuno Y
    No To Shinkei; 2002 Dec; 54(12):1041-8. PubMed ID: 12599519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Daily defined doses of parkinsonian drugs in Alcoi].
    Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
    Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
    Mizuno Y; Kondo T; Kuno S; Nomoto M; Yanagisawa N
    Clin Neuropharmacol; 2010; 33(1):1-4. PubMed ID: 19935410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
    Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease.
    Soykan I; Sarosiek I; Shifflett J; Wooten GF; McCallum RW
    Mov Disord; 1997 Nov; 12(6):952-7. PubMed ID: 9399220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and alpha-tocopherol. Parkinson Study Group.
    LeWitt P; Oakes D; Cui L
    Mov Disord; 1997 Mar; 12(2):183-9. PubMed ID: 9087976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms.
    Ondo WG; Sethi KD; Kricorian G
    Clin Neuropharmacol; 2007; 30(5):295-300. PubMed ID: 17909308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Initiation of treatment in Parkinson disease].
    Ghika J
    Praxis (Bern 1994); 1995 Sep; 84(38):1018-20. PubMed ID: 7481298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (-)Deprenyl in Parkinson's disease: a two-year study in the different evolutive stages.
    Giovannini P; Martignoni E; Piccolo I; Pacchetti C; Grassi MP; Nappi G; Caraceni T
    J Neural Transm Suppl; 1986; 22():235-46. PubMed ID: 3097258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of selegiline as initial monotherapy in early Parkinson's disease.
    Bhatia M; Jain S; Maheshwari MC
    J Assoc Physicians India; 1994 Jan; 42(1):30-2. PubMed ID: 7836244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controversies in the therapy of Parkinson's disease.
    Fahn S
    Adv Neurol; 1996; 69():477-86. PubMed ID: 8615168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moderate Parkinson's disease. Strategies for maximizing treatment.
    Silverstein PM
    Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.